ITGAM and hereditary clear cell renal cell carcinoma: In this regard, we showed that Lenvatinib, which was approved for advanced renal cell carcinoma (RCC), also reduced the percentage of TAMs, M-MDSC, and the population of CD11b+Ly6G−Ly6C− myeloid cells.